US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:01:56 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Rajasthan Royals launch ANOTHER bid to invest in cash
Next:Haiti’s international airport reopens after gang violence
You may also like
- What to stream: Lenny Kravitz, South Park, 'Dune: Part 2'
- China's securities regulator tightens delisting regulation
- Xi calls for solid efforts to further energize China's central region
- Chinese premier delivers keynote speech at China Development Forum 2024
- Warner holds out IPL hot shot Fraser
- China's securities regulator tightens delisting regulation
- Xi calls for solid efforts to further energize China's central region
- Kirill Kaprizov helps Wild end Kings' eight
- Election 2024: Nikki Haley faces a key decision on whether or not to endorse Trump